Turner, Robin M.
Dieng, Mbathio
Khanna, Nikita
Nguyen, Mai
Zeng, Jiaxu
Nijhuis, Amanda A. G.
Nieweg, Omgo E.
Einstein, Andrew J.
Emmett, Louise
Lord, Sarah J.
Menzies, Alexander M.
Thompson, John F.
Saw, Robyn P. M.
Morton, Rachael L.
Funding for this research was provided by:
Cancer Australia (1129568)
National Health and Medical Research Council (1135285, 1150989)
University of Sydney (Robinson Fellowship)
Article History
Received: 9 June 2020
Accepted: 6 October 2020
First Online: 3 January 2021
Disclosures
: John F. Thompson has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK and Provectus Inc., and travel support from GSK and Provectus Inc. Robyn P.M. Saw has received honoraria for advisory board participation from MSD Australia and Novartis, and speaking honoraria from BMS Australia. Alexander M. Menzies has received honoraia for advisory board participation from BMS, MSD, Novartis, Roche, and Pierre-Fabre, and QBiotics. Robin M. Turner, Mbathio Dieng, Nikita Khanna, Mai Nguyen, Jiaxu Zeng, Amanda A.G. Nijhuis, Omgo E. Nieweg, Andrew J. Einstein, Louise Emmett, Sarah J. Lord, and Rachael L. Morton have no disclosures to declare.